A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition

Mutsumi Hayashi, Hiroko Madokoro, Koji Yamada, Hiroko Nishida, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Malignant Mesothelioma (MM) is a highly aggressive tumor with poor prognosis. Multimodal treatments and novel molecular targeted therapies against MM are in high demand in order treat this disease effectively. We have developed a humanized monoclonal antibody YS110 against CD26 expressed in 85 % of MM cases. CD26 is thought to be involved in tumor growth and invasion by interacting with collagen and fibronectin, or affecting signal transduction processes. Methods: We evaluated the direct anti-tumor effect of YS110 against MM cell lines, NCI-H2452 and JMN, and investigated its effects on cell cycle and on the cell cycle regulator molecules. In addition, we investigated synergistic effects of YS110 and anti-tumor agent pemetrexed (PMX) against MM cell line both in vitro and in vivo. Results: YS110 suppressed the proliferation of NCI-H2452 cells by approximately 20 % in 48 h. Based on cell cycle analysis, percentage of cells in G2/M phase increased 8.0 % on the average after YS110 treatment; in addition, cell cycle regulator p21 cip/waf1 was increased and cyclin B1 was decreased after YS110 treatment. Inhibitory phosphorylation of both cdc2 (Tyr15) and cdc25C (Ser216) were elevated. Furthermore, activating phosphorylation of p38 MAPK (Thr180/Tyr182) and ERK1/2 (Thr202/Tyr204) were augmented at 24 h after YS110 treatment. PMX rapidly induced CD26 expression on cell surface and the treatment with both YS110 and PMX inhibited in vivo tumor growth accompanied by a synergistic reduction in the MIB-1 index. Conclusion: This is a first report of a novel anti-proliferative mechanism of the humanized anti-CD26 monoclonal antibody YS110, which resulted in G2/M cell cycle delay through regulation of quantity and activity of various cell cycle regulating molecules.

Original languageEnglish
Article number35
JournalCancer Cell International
Volume16
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Pemetrexed
Cell Cycle
Monoclonal Antibodies
Growth
Neoplasms
Phosphorylation
Molecular Targeted Therapy
Cyclin-Dependent Kinase Inhibitor p21
Cyclin B1
Antibodies, Monoclonal, Humanized
Cell Line
Combined Modality Therapy
G2 Phase
p38 Mitogen-Activated Protein Kinases
Therapeutics
Fibronectins
Cell Division
Signal Transduction
Collagen
Malignant Mesothelioma

Keywords

  • CD26
  • G2/M transition
  • Mesothelioma
  • Monoclonal antibody
  • Pemetrexed

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. / Hayashi, Mutsumi; Madokoro, Hiroko; Yamada, Koji; Nishida, Hiroko; Morimoto, Chikao; Sakamoto, Michiie; Yamada, Taketo.

In: Cancer Cell International, Vol. 16, No. 1, 35, 2016.

Research output: Contribution to journalArticle

Hayashi, Mutsumi ; Madokoro, Hiroko ; Yamada, Koji ; Nishida, Hiroko ; Morimoto, Chikao ; Sakamoto, Michiie ; Yamada, Taketo. / A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. In: Cancer Cell International. 2016 ; Vol. 16, No. 1.
@article{83652796e7ee43ceb1a58919142bbbea,
title = "A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition",
abstract = "Background: Malignant Mesothelioma (MM) is a highly aggressive tumor with poor prognosis. Multimodal treatments and novel molecular targeted therapies against MM are in high demand in order treat this disease effectively. We have developed a humanized monoclonal antibody YS110 against CD26 expressed in 85 {\%} of MM cases. CD26 is thought to be involved in tumor growth and invasion by interacting with collagen and fibronectin, or affecting signal transduction processes. Methods: We evaluated the direct anti-tumor effect of YS110 against MM cell lines, NCI-H2452 and JMN, and investigated its effects on cell cycle and on the cell cycle regulator molecules. In addition, we investigated synergistic effects of YS110 and anti-tumor agent pemetrexed (PMX) against MM cell line both in vitro and in vivo. Results: YS110 suppressed the proliferation of NCI-H2452 cells by approximately 20 {\%} in 48 h. Based on cell cycle analysis, percentage of cells in G2/M phase increased 8.0 {\%} on the average after YS110 treatment; in addition, cell cycle regulator p21 cip/waf1 was increased and cyclin B1 was decreased after YS110 treatment. Inhibitory phosphorylation of both cdc2 (Tyr15) and cdc25C (Ser216) were elevated. Furthermore, activating phosphorylation of p38 MAPK (Thr180/Tyr182) and ERK1/2 (Thr202/Tyr204) were augmented at 24 h after YS110 treatment. PMX rapidly induced CD26 expression on cell surface and the treatment with both YS110 and PMX inhibited in vivo tumor growth accompanied by a synergistic reduction in the MIB-1 index. Conclusion: This is a first report of a novel anti-proliferative mechanism of the humanized anti-CD26 monoclonal antibody YS110, which resulted in G2/M cell cycle delay through regulation of quantity and activity of various cell cycle regulating molecules.",
keywords = "CD26, G2/M transition, Mesothelioma, Monoclonal antibody, Pemetrexed",
author = "Mutsumi Hayashi and Hiroko Madokoro and Koji Yamada and Hiroko Nishida and Chikao Morimoto and Michiie Sakamoto and Taketo Yamada",
year = "2016",
doi = "10.1186/s12935-016-0310-9",
language = "English",
volume = "16",
journal = "Cancer Cell International",
issn = "1475-2867",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition

AU - Hayashi, Mutsumi

AU - Madokoro, Hiroko

AU - Yamada, Koji

AU - Nishida, Hiroko

AU - Morimoto, Chikao

AU - Sakamoto, Michiie

AU - Yamada, Taketo

PY - 2016

Y1 - 2016

N2 - Background: Malignant Mesothelioma (MM) is a highly aggressive tumor with poor prognosis. Multimodal treatments and novel molecular targeted therapies against MM are in high demand in order treat this disease effectively. We have developed a humanized monoclonal antibody YS110 against CD26 expressed in 85 % of MM cases. CD26 is thought to be involved in tumor growth and invasion by interacting with collagen and fibronectin, or affecting signal transduction processes. Methods: We evaluated the direct anti-tumor effect of YS110 against MM cell lines, NCI-H2452 and JMN, and investigated its effects on cell cycle and on the cell cycle regulator molecules. In addition, we investigated synergistic effects of YS110 and anti-tumor agent pemetrexed (PMX) against MM cell line both in vitro and in vivo. Results: YS110 suppressed the proliferation of NCI-H2452 cells by approximately 20 % in 48 h. Based on cell cycle analysis, percentage of cells in G2/M phase increased 8.0 % on the average after YS110 treatment; in addition, cell cycle regulator p21 cip/waf1 was increased and cyclin B1 was decreased after YS110 treatment. Inhibitory phosphorylation of both cdc2 (Tyr15) and cdc25C (Ser216) were elevated. Furthermore, activating phosphorylation of p38 MAPK (Thr180/Tyr182) and ERK1/2 (Thr202/Tyr204) were augmented at 24 h after YS110 treatment. PMX rapidly induced CD26 expression on cell surface and the treatment with both YS110 and PMX inhibited in vivo tumor growth accompanied by a synergistic reduction in the MIB-1 index. Conclusion: This is a first report of a novel anti-proliferative mechanism of the humanized anti-CD26 monoclonal antibody YS110, which resulted in G2/M cell cycle delay through regulation of quantity and activity of various cell cycle regulating molecules.

AB - Background: Malignant Mesothelioma (MM) is a highly aggressive tumor with poor prognosis. Multimodal treatments and novel molecular targeted therapies against MM are in high demand in order treat this disease effectively. We have developed a humanized monoclonal antibody YS110 against CD26 expressed in 85 % of MM cases. CD26 is thought to be involved in tumor growth and invasion by interacting with collagen and fibronectin, or affecting signal transduction processes. Methods: We evaluated the direct anti-tumor effect of YS110 against MM cell lines, NCI-H2452 and JMN, and investigated its effects on cell cycle and on the cell cycle regulator molecules. In addition, we investigated synergistic effects of YS110 and anti-tumor agent pemetrexed (PMX) against MM cell line both in vitro and in vivo. Results: YS110 suppressed the proliferation of NCI-H2452 cells by approximately 20 % in 48 h. Based on cell cycle analysis, percentage of cells in G2/M phase increased 8.0 % on the average after YS110 treatment; in addition, cell cycle regulator p21 cip/waf1 was increased and cyclin B1 was decreased after YS110 treatment. Inhibitory phosphorylation of both cdc2 (Tyr15) and cdc25C (Ser216) were elevated. Furthermore, activating phosphorylation of p38 MAPK (Thr180/Tyr182) and ERK1/2 (Thr202/Tyr204) were augmented at 24 h after YS110 treatment. PMX rapidly induced CD26 expression on cell surface and the treatment with both YS110 and PMX inhibited in vivo tumor growth accompanied by a synergistic reduction in the MIB-1 index. Conclusion: This is a first report of a novel anti-proliferative mechanism of the humanized anti-CD26 monoclonal antibody YS110, which resulted in G2/M cell cycle delay through regulation of quantity and activity of various cell cycle regulating molecules.

KW - CD26

KW - G2/M transition

KW - Mesothelioma

KW - Monoclonal antibody

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=85007482763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007482763&partnerID=8YFLogxK

U2 - 10.1186/s12935-016-0310-9

DO - 10.1186/s12935-016-0310-9

M3 - Article

AN - SCOPUS:85007482763

VL - 16

JO - Cancer Cell International

JF - Cancer Cell International

SN - 1475-2867

IS - 1

M1 - 35

ER -